CD30 associates with EBER-EBV but not HCV-NS3 in T-cell non-Hodgkin lymphoma by Rizki Amalia Juwita, Lili Ananta Saputra, Ika Fiilasari, Mardiah Suci Hardianti, Nungki Anggorowati

Subjects: Get full text

Targeting CD30L in B-cell non-Hodgkin lymphoma: novel peptide conjugates and their therapeutic potential by Chaowen Shi, Tianzheng Lan, Yufeng Gao, Zhiquan Liang, Yafei Zhang, Yanbei Tu, Hanqing Liu, Zhigang Tu

Subjects: Get full text

Preliminary biological evaluation of 123I-labelled anti-CD30-LDM in CD30-positive lymphomas murine models by Jianhua Gong, Feihu Guo, Weihua Cheng, Hongqiang Fan, Qingfang Miao, Jigang Yang

Subjects: Get full text

Histologic and Immunohistochemical Patterns in Lymphomatoid Papulosis: A Systematic Review of Published Cases by Torben Fricke, Werner Kempf, Michael P. Schön, Christina Mitteldorf

Subjects: Get full text

Co-occurrence of myositis and neuropathy after anti-CD30 therapy in a late-adolescent Hodgkin lymphoma patient by Adela Della Marina, Lydia Rink, Andreas Hentschel, Michael M. Schündeln, Christopher Nelke, Heike Kölbel, Calvin Tucht, Vera Dobelmann, Tobias Ruck, Tim Hagenacker, Teresinha Evangelista, Ulrike Schara-Schmidt, Andreas Roos

Subjects: Get full text

Hodgkin lymphoma: A clinicopathological and immunophenotypic study by Kaumudi Konkay, Tara Roshni Paul, Shantveer G Uppin, Digumarti Raghunadha Rao

Subjects: Get full text

Case Report: Bispecific CD20/CD30-targeted chimeric antigen receptor T-cell therapy for non-Hodgkin’s lymphoma by Yuejiao Huang, Yiming Gong, Xiang Liu, Huaying Ruan, Jinhua Lu, Hosein Kouros-Mehr, Hong Liu, Han Wang

Subjects: Get full text

Brentuximab vedotin in children and adolescents with Hodgkin’s lymphoma and anaplastic large cell lymphoma – literature review and own experience by N. V. Myakova, D. A. Evstratov, D. S. Abramov, D. M. Konovalov, A. V. Pshonkin, D. V. Litvinov

Subjects: Get full text

Lymphomatoid Papulosis Type E With T-Cell Receptor Gamma Positivity by Namasondhi A, Rutnin S, Jerasutus S, Boonsakan P, Triyangkulsri K

Subjects: “…cd30…”
Get full text

An Ulcerated Nodule on the Toe in an Elderly Patient: A Quiz by Ziqi Liu, Qiaoan Zhang, Lianjun Chen, Qiong Huang

Subjects: Get full text

PRIMARY PALATAL ALK-NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA: RARITY TREATED SUCCESSFULLY WITH BRENTUXIMAB VEDOTIN by Müjgan Çözeli, Elif Canbolat Hirfanoğlu, Birol Güvenç

Subjects: Get full text

Molecular heterogeneity of CD30+ peripheral T-cell lymphoma with prognostic significance and therapeutic implications: a retrospective multi-centre studyResearch in context by Yu-Jia Huo, Shu Cheng, Hong-Mei Yi, Ting Niu, Lei Fan, Guo-Hui Cui, Fu-Ling Zhou, Xian-Min Song, Fei Li, Ou Bai, Xiao-Jing Yan, Jun Shi, Ming-Ci Cai, Yao-Hui Huang, Lei Dong, Jie Xiong, Song Hu, Yu-Ran Qiu, Yan Zhao, Peng-Peng Xu, Li Wang, Min Lu, Hong-Mei Jing, Wei-Li Zhao

Subjects: Get full text

Breast implant-associated anaplastic large cell lymphoma: a diagnostic challenge by Ana Paula De-Azambuja, Anne Karoline Groth, Juliana Jung, Fabiola Gevert, Samir Kanaan Nabhan

Subjects: Get full text

TREATMENT OF RELAPSE AND REFRACTORY HODGKIN LYMPHOMA by E. A. Baryakh

Subjects: Get full text

The Role of Reed-Sternberg CD30 Receptor and Lymphocytes in Pathogenesis of Disease and Its Implication for Treatment by Ikhwan Rinaldi

Subjects: Get full text

The Role of Reed-Sternberg CD30 Receptor and Lymphocytes in Pathogenesis of Disease and Its Implication for Treatment by Ikhwan Rinaldi

Subjects: Get full text

CD30, CD15, CD50, and PAX5 Expressions as Diagnostic Markers for Hodgkin Lymphoma (HL) and Systemic Anaplastic Large Cell Lymphoma (sALCL) by Dody Ranuhardy, Evlina Suzanna, Resti M Sari, Dwi W Hadisantoso, Rizka Andalucia, Arif Abdillah

Subjects: “…CD30…”
Get full text

CD30, CD15, CD50, and PAX5 Expressions as Diagnostic Markers for Hodgkin Lymphoma (HL) and Systemic Anaplastic Large Cell Lymphoma (sALCL) by Dody Ranuhardy, Evlina Suzanna, Resti M Sari, Dwi W Hadisantoso, Rizka Andalucia, Arif Abdillah

Subjects: “…CD30…”
Get full text

PHARMACOECONOMIC ANALYSIS OF BRENTUXIMAB VEDOTIN THERAPY IN RELAPSED OR REFRACTORY CD30+ SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA IN PATIENTS OVER 18 YEARS OF AGE: HEALTH BUDGET IMP... by A. S. Kolbin, I. A. Vilum, М. A. Proskurin, Yu. E. Balykina

Subjects: “…relapsed or refractory cd30+ systemic anaplastic large cell lymphoma…”
Get full text

COST-EFFECTIVENESS ANALYSIS OF BRENTUXIMAB VEDOTIN IN ADULTS WITH RELAPSED OR REFRACTORY HODGKIN’S LYMPHOMA by G. R. Khachatryan, D. V. Fedyaev, M. V. Avxentyeva, V. S. Dombrovskiy

Subjects: “…relapsed or refractory cd30-positive hodgkin’s lymphoma…”
Get full text